CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Control (albumin 5%)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug649 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.71

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002032 Bulimia NIH 1.00
D001068 Feeding and Eating Disorders NIH 0.50

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0100739 Bulimia HPO 1.00

There is one clinical trial.

Clinical Trials

1 A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases

This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in two groups, RT PCR-positive and asymptomatic or mildly symptomatic at baseline (group B) and PCR-negative at baseline (group C). Both groups will be randomized 1:1 to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%).

NCT04390503 SARS-CoV 2 COVID-19 Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma) Biological: Control (albumin 5%)

Primary Outcomes

Description: The efficacy of treatment will be determined by rating disease severity on Day 28, or last rating evaluated, using a seven-category severity scale.

Measure: Rate of Severe Disease

Time: Up to 28 days

Secondary Outcomes

Description: To compare the rate of measurable anti-SARS-CoV-2 titers between recipients of CP (anti-SARS-CoV-2 plasma) versus control (albumin 5%).

Measure: Rate of measurable anti-SARS-CoV-2 titers

Time: Up to 90 days

Description: Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).

Measure: Rate of SARS-CoV-2 PCR Positivity

Time: Up to 28 days

Description: Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).

Measure: Duration of SARS-CoV-2 PCR Positivity

Time: Up to 28 days

Description: Compare the levels of SARS-CoV-2 RNA between the recipients of antiSARS-CoV-2 plasma and control (albumin 5%)

Measure: Levels of SARS-CoV-2 RNA

Time: Up to 28 days

No related HPO nodes (Using clinical trials)